Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...

Vepdegestrant met the primary endpoint in ESR1-mutant breast cancer, significantly improving progression-free survival over fulvestrant. The trial did not achieve statistical significance for PFS ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

UC San Diego's Moores Cancer Center has received a $1 million donation from pharmaceutical giant Pfizer to support early ...

Funding will support Moores Cancer Center’s efforts to develop a unique, large-scale program to drive early detection and ...